Grünenthal and DKSH Partnered for Pain Medication Access
The companies have expanded their existing alliance to distribute four pain therapies across eight Asia-Pacific markets.
Updated on Sept. 28, 2026 in Arthritis
Live Poll
Do you trust that new corporate partnerships will improve patient access to essential pain medications?
Grünenthal and DKSH have signed a new partnership agreement to bring four pain medications to patients in eight Asia-Pacific countries. DKSH will oversee the marketing, sales, and distribution of the treatments, while Grünenthal handles manufacturing.
Why it matters
The partnership aims to address the growing regional healthcare burden caused by chronic diseases and an ageing population. By leveraging DKSH's local expertise, Grünenthal seeks to expand access to innovative pain therapies in high-demand markets.
The agreement includes four specific medications, such as the 8% concentration Qutenza topical system and therapies approved for use in patients as young as 6 years for Palexia or 12 years for Zomig. DKSH will manage operations across eight distinct markets.
The players
Grünenthal
This is a global research-based pharmaceutical company that focuses on pain management and related therapies.
DKSH
This is a market expansion services provider that assists companies in growing their business in Asia and beyond.
The details
Under this agreement, DKSH will seek local regulatory marketing authorizations for Qutenza, Vimovo, Palexia, and Zomig in Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam. Grünenthal will supply the medicines through its integrated global manufacturing network to ensure consistent availability in the region.
Timeline
The companies first established their commercial partnership in 2023.
The new expanded agreement was officially announced on September 28, 2026.
Health Landscape
This agreement reflects a broader shift toward multinational pharmaceutical companies utilizing regional distributors to navigate complex regulatory environments and healthcare infrastructure in Asia. It follows patterns established by the International Association for the Study of Pain global pain management initiatives to improve access in underserved regions.
Patients in the eight participating markets may see improved access to specialized pain treatments that were previously unavailable or difficult to source. The partnership intends to streamline the availability of these specific medications, potentially reducing wait times for those suffering from chronic pain conditions.
The takeaway
The collaboration highlights the importance of regional distribution networks in delivering essential chronic disease therapies to ageing populations. Patients should consult with local healthcare providers to determine if these specific medications align with their current treatment plans as authorizations move forward.
Further reading
Learn more about the latest innovations and management strategies in the Arthritis section.
Live Poll
Do you trust that new corporate partnerships will improve patient access to essential pain medications?
